1-Deamino-8-D-arginine vasopressin and cryoprecipitate in variant von Willebrand disease.
The effect of infusing DDAVP and cryoprecipitate either singly or in combination was studied in a patient with variant von Willebrand disease. Both DDAVP and cryoprecipitate caused only partial correction in the hemostatic defect when used as a single agent. A combination of DDAVP and cryoprecipitate induced a complete correction of the hemostatic defect as well as factor VIII related properties.
D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005169:Factor VIII / Q000008:administration & dosage / Q000627:therapeutic use*; D005340:Fibrinogen / Q000008:administration & dosage / Q000627:therapeutic use*; D014644:Genetic Variation; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D014842:von Willebrand Diseases / Q000188:drug therapy / Q000235:genetics*
C026912:cryoprecipitate coagulum; D005169:Factor VIII; D005340:Fibrinogen; D003894:Deamino Arginine Vasopressin